Invention Grant
- Patent Title: S100A8/S100A9-induced immunotolerance in newborn subjects
-
Application No.: US16347907Application Date: 2017-11-06
-
Publication No.: US11253570B2Publication Date: 2022-02-22
- Inventor: Dorothee Viemann , Johannes Roth , Thomas Vogl
- Applicant: Westfälische Wilhelms-Universität Münster , Medizinische Hochschule Hannover (MHH)
- Applicant Address: DE Münster; DE Hannover
- Assignee: Westfälische Wilhelms-Universität Münster,Medizinische Hochschule Hannover (MHH)
- Current Assignee: Westfälische Wilhelms-Universität Münster,Medizinische Hochschule Hannover (MHH)
- Current Assignee Address: DE Münster; DE Hannover
- Agency: Kagan Binder, PLLC
- Priority: LU93291 20161107
- International Application: PCT/EP2017/078291 WO 20171106
- International Announcement: WO2018/083291 WO 20180511
- Main IPC: A61K38/17
- IPC: A61K38/17 ; A61P29/00 ; G01N33/96 ; G01N33/68
Abstract:
The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-κB-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-κB-associated postnatal inflammatory disorder.
Information query
IPC分类:
